Epigenetic inactivation of DNA repair in breast cancer

Somaira Nowsheen; Khaled Aziz; Phuoc T. Tran; Vassilis G. Gorgoulis; Eddy S. Yang; Alexandros G. Georgakilas

doi:10.1016/j.canlet.2012.05.015

Epigenetic inactivation of DNA repair in breast cancer

Somaira Nowsheen, Khaled Aziz, Phuoc T. Tran, Vassilis G. Gorgoulis, Eddy S. Yang, Alexandros G. Georgakilas

Radiation Medicine

Research output: Contribution to journal › Review article › peer-review

26 Citations (SciVal)

Abstract

The study of epigenetic mechanisms in cancer, such as DNA methylation and histone modifications, has revealed a plethora of events that contribute to cancer through stable changes in the expression of genes critical to transformation pathways. In this mini review we look at the different epigenetic modifications prevalent in this neoplastic phenotype, focusing on breast cancer. Most encouragingly, research in epigenetics has led to improved survival of patients with certain forms of lymphoma and leukemia through the use of drugs that alter DNA methylation and histone acetylation. Thus, we look at the clinical utility of targeting epigenetic pathways. In addition, we explore numerous other clinical applications of epigenetics, in areas such as cancer screening and early detection, prevention, classification for epidemiology and prognostic purposes, and predicting outcomes after standard therapy.

Original language	English
Pages (from-to)	213-222
Number of pages	10
Journal	Cancer Letters
Volume	342
Issue number	2
DOIs	https://doi.org/10.1016/j.canlet.2012.05.015
State	Published - Jan 28 2014

Bibliographical note

Funding Information:
We apologize to those investigators whose meritorious work could not be cited due to space limitations. This work was supported by funds provided by the Biology Department, East Carolina University (to A.G.G.), IMPACT Award from the Department of Radiation Oncology, University of Alabama-Birmingham Comprehensive Cancer Center, and University of Alabama-Birmingham School of Medicine (to E.S.Y.).

Keywords

Biomarkers
Breast cancer
Cancer
Carcinogenesis
DNA damage
Epigenetics
Personalized treatment

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.canlet.2012.05.015

Cite this

@article{d9a7755886ba4b66a8b606568faa34dc,

title = "Epigenetic inactivation of DNA repair in breast cancer",

abstract = "The study of epigenetic mechanisms in cancer, such as DNA methylation and histone modifications, has revealed a plethora of events that contribute to cancer through stable changes in the expression of genes critical to transformation pathways. In this mini review we look at the different epigenetic modifications prevalent in this neoplastic phenotype, focusing on breast cancer. Most encouragingly, research in epigenetics has led to improved survival of patients with certain forms of lymphoma and leukemia through the use of drugs that alter DNA methylation and histone acetylation. Thus, we look at the clinical utility of targeting epigenetic pathways. In addition, we explore numerous other clinical applications of epigenetics, in areas such as cancer screening and early detection, prevention, classification for epidemiology and prognostic purposes, and predicting outcomes after standard therapy.",

keywords = "Biomarkers, Breast cancer, Cancer, Carcinogenesis, DNA damage, Epigenetics, Personalized treatment",

author = "Somaira Nowsheen and Khaled Aziz and Tran, {Phuoc T.} and Gorgoulis, {Vassilis G.} and Yang, {Eddy S.} and Georgakilas, {Alexandros G.}",

note = "Funding Information: We apologize to those investigators whose meritorious work could not be cited due to space limitations. This work was supported by funds provided by the Biology Department, East Carolina University (to A.G.G.), IMPACT Award from the Department of Radiation Oncology, University of Alabama-Birmingham Comprehensive Cancer Center, and University of Alabama-Birmingham School of Medicine (to E.S.Y.).",

year = "2014",

month = jan,

day = "28",

doi = "10.1016/j.canlet.2012.05.015",

language = "English",

volume = "342",

pages = "213--222",

number = "2",

}

TY - JOUR

T1 - Epigenetic inactivation of DNA repair in breast cancer

AU - Nowsheen, Somaira

AU - Aziz, Khaled

AU - Tran, Phuoc T.

AU - Gorgoulis, Vassilis G.

AU - Yang, Eddy S.

AU - Georgakilas, Alexandros G.

N1 - Funding Information: We apologize to those investigators whose meritorious work could not be cited due to space limitations. This work was supported by funds provided by the Biology Department, East Carolina University (to A.G.G.), IMPACT Award from the Department of Radiation Oncology, University of Alabama-Birmingham Comprehensive Cancer Center, and University of Alabama-Birmingham School of Medicine (to E.S.Y.).

PY - 2014/1/28

Y1 - 2014/1/28

N2 - The study of epigenetic mechanisms in cancer, such as DNA methylation and histone modifications, has revealed a plethora of events that contribute to cancer through stable changes in the expression of genes critical to transformation pathways. In this mini review we look at the different epigenetic modifications prevalent in this neoplastic phenotype, focusing on breast cancer. Most encouragingly, research in epigenetics has led to improved survival of patients with certain forms of lymphoma and leukemia through the use of drugs that alter DNA methylation and histone acetylation. Thus, we look at the clinical utility of targeting epigenetic pathways. In addition, we explore numerous other clinical applications of epigenetics, in areas such as cancer screening and early detection, prevention, classification for epidemiology and prognostic purposes, and predicting outcomes after standard therapy.

AB - The study of epigenetic mechanisms in cancer, such as DNA methylation and histone modifications, has revealed a plethora of events that contribute to cancer through stable changes in the expression of genes critical to transformation pathways. In this mini review we look at the different epigenetic modifications prevalent in this neoplastic phenotype, focusing on breast cancer. Most encouragingly, research in epigenetics has led to improved survival of patients with certain forms of lymphoma and leukemia through the use of drugs that alter DNA methylation and histone acetylation. Thus, we look at the clinical utility of targeting epigenetic pathways. In addition, we explore numerous other clinical applications of epigenetics, in areas such as cancer screening and early detection, prevention, classification for epidemiology and prognostic purposes, and predicting outcomes after standard therapy.

KW - Biomarkers

KW - Breast cancer

KW - Cancer

KW - Carcinogenesis

KW - DNA damage

KW - Epigenetics

KW - Personalized treatment

UR - http://www.scopus.com/inward/record.url?scp=84888199628&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84888199628&partnerID=8YFLogxK

U2 - 10.1016/j.canlet.2012.05.015

DO - 10.1016/j.canlet.2012.05.015

M3 - Review article

C2 - 22634493

AN - SCOPUS:84888199628

VL - 342

SP - 213

EP - 222

IS - 2

ER -

Epigenetic inactivation of DNA repair in breast cancer

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this